

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

Recombinant Cyn. monkey ACE2 protein, C-His-Avi (HEK293)

Catalog Number: bs-47021P Concentration: >0.5 mg/ml

AA Seq: 18-739/805

Predicted MW: 86.5

Detected MW: Due to glycosylation, the protein migrates to 95-110 kDa based on Tris-Bis PAGE result.

Tags: C-His-Avi
Activity: Not tested

Endotoxin: <1.0 EU/µg as determined by LAL

Purity: >95% as determined by Tris-Bis PAGE; >95% as determined by SEC-HPLC

Purification: AC

Form: Lyophilized

Storage: Lyophilized from 0.22um filtered solution in PBS (pH7.4) with 5mM DTT. Normally 5%

trehalose is added as protectant before Lyophilization.


Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.

Background: The protein encoded by this gene belongs to the angiotensin-converting enzyme family of


dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. The organ- and cell-specific expression of this gene suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronaviruses SARS and HCoV-

NL63. [provided by RefSeq, Jul 2008]


VALIDATION IMAGES




Cynomolgus ACE2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.



The purity of Cynomolgus ACE2 is greater than 95% as determined by SEC-HPLC.



Recombinant Cynomolgus ACE2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.



The purity of Cynomolgus ACE2 is greater than 95% as determined by SEC-HPLC

PRODUCT SPECIFIC PUBLICATIONS

[IF=4.38] Lalioti, Vasiliki. et al. Cell surface detection of vimentin, ACE2 and SARS-CoV-2 Spike proteins reveals selective colocalization at primary cilia. SCI REP-UK. 2022 Apr;12(1):1-19 Other; . 10.1038/s41598-022-11248-y